tislelizumab
marker therapeutics,beigene,leap therapeutics
['$lptx', 'marker ', 'leaptherap']
 some of the $lptx confusion about the abstracts vs pr may be due to the "updated orr, dor, pfs and additional correlative biomarker evaluation" that will only "be reported." at the presentation time. #sitc2022